SCLC
Consolidation Immunotherapy in Limited-Stage Small Cell Lung Cancer Improves Overall Survival
After platinum-based chemoradiotherapy, a consolidation immunotherapy regimen significantly improved overall ...
JUNE 12, 2024
Study Defines SCLC Subtypes With Distinct Therapeutic Vulnerabilities
Countering the one-size-fits-all treatment for small-cell lung cancer, investigators classified the malignancy into ...
FEBRUARY 2, 2021
FDA Approves Zepzelca as New Option for Metastatic SCLC
The FDA granted accelerated approval to lurbinectedin (Zepzelca, Pharma Mar/Jazz) to treat adults with metastatic ...
JUNE 18, 2020
FDA Approves Cyramza Plus Erlotinib for EGFR-Mutated Metastatic NSCLC
The FDA approved the use of ramucirumab (Cyramza, Lilly) in combination with erlotinib for first-line treatment of ...
JUNE 3, 2020
Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or ...
APRIL 6, 2020
Keytruda Gains Approval for Treatment of SCLC
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have ...
JUNE 20, 2019
FDA Approves Opdivo as Third-Line Rx for SCLC
The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with ...
AUGUST 21, 2018
G-CSF Not Detrimental With Concurrent Chemo-RT in Limited-Stage SCLC
Supportive care for patients with early, limited-stage small cell lung cancer using G-CSF along with concurrent ...
DECEMBER 29, 2017
Statins Do Not Benefit Patients With Lung Cancer
It was initially thought that lowering cholesterol levels could impair the development and growth of cancer cells, ...
FEBRUARY 28, 2017
First Biomarker-Directed Therapy in SCLC Is Impressive
Chicago—Unprecedented response rates were achieved with a novel antibody drug conjugate for relapsed or ...
AUGUST 23, 2016
PharmaMar To Test PM1183 With Doxorubicin in SCLC
Madrid-based company PharmaMar announced the start of their Phase III study, ATLANTIS, on Aug. 2.
AUGUST 12, 2016